Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

33.3%

3 terminated/withdrawn out of 9 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

117%

7 of 6 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 1

5(55.6%)

Phase 3

3(33.3%)

Phase 2

1(11.1%)

9Total

Phase 1(5)

Phase 3(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04765202Phase 1Terminated

StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns

Role: lead

NCT05517902Phase 3Completed

StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

Role: lead

NCT04123548Phase 3Completed

StrataGraft® Skin Tissue Expanded Access at Specific Study Sites ( StrataCAT )

Role: lead

NCT03005054Phase 2Terminated

StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects

Role: lead

NCT03005106Phase 3Completed

StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements

Role: lead

NCT04134143Phase 1Terminated

Multiple Applications of ExpressGraft-C9T1 Skin Tissue as a Treatment for Diabetic Foot Ulcers

Role: lead

NCT00618839Phase 1Completed

StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects

Role: lead

NCT01437852Phase 1Completed

StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns

Role: lead

NCT02657876Phase 1Completed

ExpressGraft-C9T1 Skin Tissue as a Treatment of Diabetic Foot Ulcers

Role: lead

All 9 trials loaded